INIS
tumors
100%
genes
100%
nerves
100%
proteins
37%
tissues
37%
probes
25%
patients
25%
chromosomes
25%
dna
25%
cancer
25%
comparative evaluations
12%
levels
12%
data
12%
evaluation
12%
validation
12%
amplification
12%
therapy
12%
fluorescence
12%
centromeres
12%
metastases
12%
in-situ hybridization
12%
biopsy
12%
Keyphrases
Topoisomerase II
100%
Malignant Peripheral Nerve Sheath Tumor (MPNST)
100%
Clinical Outcomes
100%
Tissue Microarray
30%
Tumor
20%
High-level Expression
10%
In Situ
10%
Clinical Data
10%
Centromere
10%
Metastasis
10%
Gene Expression Profiling
10%
Clinical Significance
10%
Copy number
10%
Gene Expression Analysis
10%
Protein Expression
10%
Aggressive Tumor
10%
CDNA Microarray Analysis
10%
DNA Copy number
10%
Clinical Endpoints
10%
Clinical Validation
10%
CDNA Microarray
10%
Neurofibroma
10%
Adverse Outcomes
10%
Gene Probes
10%
Overexpressed Genes
10%
Predictive Factors
10%
Cancer-specific Survival
10%
Interphase Fluorescence in Situ Hybridization
10%
Encoded Protein
10%
Chromosome Arms
10%
Neuroscience
Nerve Sheath Tumor
100%
Peripheral Nerve
100%
DNA Gyrase
100%
cDNA Microarray
33%
Gene Expression
33%
Expression Analysis
16%
Neurofibroma
16%
Protein Expression
16%
Chromosome Arm
16%
In Situ Hybridization
16%
Gene Dosage
16%
Interphase
16%
Centromere
16%
Biochemistry, Genetics and Molecular Biology
TOP2A
100%
DNA Gyrase
100%
Tissue Microarray
50%
Gene Expression Profiling
33%
cDNA Microarray
33%
Candidate Gene
16%
Gene Dosage
16%
Centromere
16%
Protein Expression
16%
Fluorescence in Situ Hybridization
16%
Cancer Specific Survival
16%
Gene Probe
16%
Chromosome Arm
16%
Interphase
16%
Medicine and Dentistry
DNA Topoisomerase (ATP Hydrolysing)
100%
Tissue Microarray
50%
Neoplasm
33%
cDNA Microarray
33%
Gene Expression Profiling
33%
Metastatic Carcinoma
16%
Fluorescence in Situ Hybridization
16%
Microarray Analysis
16%
Protein Expression
16%
Malignant Neoplasm
16%
Chromosome Arm
16%
Predictive Factor
16%
Plexiform Neurofibroma
16%
Clinical Significance
16%
Interphase
16%
Centromere
16%
Biopsy Technique
16%